AstraZeneca PLC
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AZNCF research report →
About the company
AstraZeneca PLC functions as a global biopharmaceutical enterprise, committed to the entire process of pharmaceutical innovation, spanning from the initial discovery and development stages to the manufacturing and market introduction of its prescription medications. The company boasts a comprehensive portfolio of drugs addressing a diverse array of therapeutic areas. This encompasses a robust selection for oncology, featuring key treatments such as Calquence, Enhertu, and Tagrisso, alongside vital therapies for cardiovascular, renal, and metabolic conditions, including Farxiga/Forxiga and Brilinta/Brilique.
- CEO
- Pascal Claude Roland Soriot
- IPO
- 2009
- Employees
- 94,300
- HQ
- Cambridge, GB
Price Chart
- Market Cap
- $294.40B
- P/E
- 28.60
- P/S
- 4.92
- P/B
- 6.32
- EV/EBITDA
- 15.86
- Div Yield
- 1.63%
- Gross Margin
- 79.71%
- Op Margin
- 23.53%
- Net Margin
- 17.19%
- ROE
- 22.41%
- ROIC
- 12.88%
- Revenue
- $58.74B · 8.63%
- Net Income
- $10.22B · 45.34%
- EPS
- $6.60 · 45.37%
- Op Income
- $13.74B
- FCF YoY
- 19.18%
- 52W High
- $209.48
- 52W Low
- $122.26
- 50D MA
- $183.86
- 200D MA
- $161.39
- Beta
- 0.19
- Avg Volume
- 161.84K
Get TickerSpark's AI analysis on AZNCF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our AZNCF coverage
Recent articles, reports, and earnings notes.
No research on AZNCF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AZNCF report →Similar companies
Peers in the same neighborhood.